Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

To make things a little less confusing, we’re here with all the info you need about popular weight loss med Mounjaro.

Now, new clinical trial results suggest that an oral form of this medication may be coming soon—and the results so far are ...

A former college athlete, 51-year-old Charles never thought he'd have to worry about his weight. But football injuries and a ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

Doctors suggest that anybody with a Body mass index of over 30 or greater than 27 is advised to try weight loss drugs.

Eli Lilly shares fell after the company’s oral drug showed less weight loss than hoped. It could still be huge.

Kym Whitley partners with Eli Lilly to share her transformative experience using Zepbound, an obesity management medication.

Eli Lilly says it plans to apply for U.S. Food and Drug Administration (FDA) approval by the end of the year to market the ...

Eli Lilly raised its full-year profit and sales forecast on Thursday, betting on surging demand for its blockbuster ...

FOR years, Emma Morris hid from cameras, avoided mirrors and felt like a prisoner in her own body because of her weight. But ...